Thoracoscopic rebiopsy to detect the T790M mutation after postoperative recurrence.

doi:10.1093/icvts/ivy107

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Thoracoscopic rebiopsy to detect the T790M mutation after postoperative recurrence.

Interactive cardiovascular and thoracic surgery - 1 Oct 2018

Hamaji Masatsugu, Motoyama Hideki, Menju Toshi, Chen-Yoshikawa Toyofumi-Fengshi, Sonobe Makoto, Kim Young Hak, Date Hiroshi

Abstract excerpt

After pulmonary resection for non-small-cell lung cancer, some patients with postoperative recurrence and mutated epidermal growth factor receptor (EGFR) subsequently receive EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Osimertinib may be efficacious if those patients become resistant to the 1st-line EGFR-TKI because of the T790M mutation. We recently performed thoracoscopic rebiopsy to detect the T790M mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Carcinoma, Non-Small-Cell Lung
Share to DNA, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Neoplasm Recurrence, Local

Share to Pneumonectomy

Share to Postoperative Period

Source

Open in PubMed

Identifiers

PMID: 29618075
DOI: 10.1093/icvts/ivy107

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.